Title: Pharmacovigilance Industry Is worth Usd 6 Billion and Is Expected to continue to grow at 12% Per Year

Abstract:

The current trends are as follows

Increased Focus on Quality, Compliance and Quality Management System, Requirements of Audit and Inspection readiness Process Enhancements, Changes, Improvements Further adoption of Technology and Tools, Database migrations Focus on Data Analytics and Trends

Organisational Culture Enhancement –Focus on People Development, Training and Retention Change Management – Mergers / Acquisitions and Integrations  The Challenges are as follows Requirement of skilled resources Retention of talent People Development Needs Standard Operating Procedures Better quality and compliance Need for better productivity Adoption of Technology Reduce cost per transaction Improve Efficiency The Opportunities are as follows People (Organisation Culture) Process (Operational Excellence) Technology (Digital Transformation)

Biography:

Gurpreet Singh is currently the Vice President, Global Head of Pharmacovigilance at Freyr. He is based in UK and has a total of 17+years' experience in Pharma Industry of which 16+ years have been in Global Drug Development. During these years he has had the opportunity to work with some top Global companies like Cognizant, Tata Consultancy, Novartis and Parexel.  At Novartis he was the Global Head of PV Operations managing all Global PV activities. At Parexel he was the Senior Director PV Operations responsible for managing PV projects of top Global Pharma and Biotech companies. Gurpreet is a certified Six Sigma and Project Management Professional. He has keen interest in Digital Transformation and Organization Culture and has successfully led various projects during his tenure in the Pharma Industry. He is an avid runner and a speaker at various PV conferences.